| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Morena Fasano, Mario Pirozzi, Pasquale Vitale, Vincenzo Damiano, Graziana Ronzino, Stefano Farese, Vincenzo Carfora, Giuseppina Ciccarelli, Ilaria Di Giovanni, Sergio Facchini, Gregorio Cennamo, Michele Caraglia, Fortunato Ciardiello and Raffaele Addeo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Morena Fasano, MD, PhD, Associate Research Scientist, Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Antonio Vivaldi 45-81100 Caserta, Naples 80120, Italy. morena.fasano@unicampania.it |
| Key Words |
Taxanes; Immunotherapy; Head and neck cancer; Alcohol; Smoking; Body mass index |
| Core Tip |
The aim of this retrospective observational study was to evaluate the efficacy of paclitaxel as second-line treatment for patients with metastatic squamous cell carcinoma of the head and neck (SCCHN), providing unique real-world clinical experience. The observations reflect the experience of clinicians in an era before the advent of cancer immunotherapy. The results showed good efficacy of paclitaxel, and importantly, a favorable toxicity profile. These findings demonstrate that paclitaxel is a valid therapeutic option for patients with SCCHN who received prior therapy. |
| Publish Date |
2024-10-22 08:28 |
| Citation |
<p>Fasano M, Pirozzi M, Vitale P, Damiano V, Ronzino G, Farese S, Carfora V, Ciccarelli G, Di Giovanni I, Facchini S, Cennamo G, Caraglia M, Ciardiello F, Addeo R. Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study. <i>World J Clin Oncol</i> 2024; 15(12): 1468-1480</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i12/1468.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i12.1468 |
